Aim: Advanced BCC can cause considerable morbidity and severe disfigurement, leading to emotional and psychological distress and reduced QOL. The hedgehog (Hh) pathway is aberrantly activated in ≥ 95% of BCCs. Sonidegib blocks the Hh pathway by selective inhibition of smoothened. In a phase 2 study (BOLT; NCT01327053), patients ( pts) with advanced BCC achieved meaningful disease control with sonidegib. The impact on pt-reported QOL is presented here. Methods: Pts with locally advanced BCC (LaBCC) not amenable to curative surgery or radiotherapy (n = 194) or metastatic BCC (mBCC; n = 36) were randomized to receive sonidegib 200 or 800 mg (1:2) once daily. QOL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the associated Head and Neck cancer module (H&N35). Prespecified subscale scores included physical functioning, social functioning, pain, and fatigue for C30, and trouble with social contact, head and neck pain, and weight loss for H&N35. Results: Questionnaires were completed at baseline (BL) and ≥ 1 post-BL time point by 88.7% (C30) and 90.0% (H&N35) of pts. Maintenance or improvement of scores on the C30 and H&N35 scales was experienced by the majority of pts, with consistent effects in those with LaBCC and mBCC (Table) . Descriptive analysis of mean scores generally showed maintenance in each scale through week 73 with both doses. Median time to deterioration (> 10-point worsening without subsequent improvement) was 13.7 months for fatigue and 16.6 months for weight loss, and not estimable (NE) for other scales with 200 mg; and 11.1, 11.3, 5.6, and 16.5 months for physical functioning, social functioning, fatigue, and weight loss, respectively, and NE for other scales with 800 mg. Conclusions: Overall, pts treated with sonidegib in the BOLT trial maintained or improved their functioning and QOL, supporting the treatment effect observed in pts with advanced BCC and the favorable tolerability of sonidegib. 
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